Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
64 hedge funds and large institutions have $96.3M invested in Pear Therapeutics, Inc. Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 24 increasing their positions, 10 reducing their positions, and 9 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 10
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
7% more funds holding
Funds holding: 60 → 64 (+4)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
29% less call options, than puts
Call options by funds: $5K | Put options by funds: $7K
43% less capital invested
Capital invested by funds: $168M → $96.3M (-$71.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Scoggin Management
New York
|
+$1.04M |
| 2 |
BlackRock
New York
|
+$930K |
| 3 |
State Street
Boston,
Massachusetts
|
+$225K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$113K |
| 5 |
Jane Street
New York
|
+$94.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.06M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$404K |
| 3 |
AIM
Acropolis Investment Management
St. Louis,
Missouri
|
-$336K |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
-$335K |
| 5 |
Rafferty Asset Management
New York
|
-$332K |
PEAR Hedge Fund Activity: Q4 2022 in Review
64 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q4 2022, worth a combined $96.3M — down 43% from $168M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new PEAR positions and 9 closed out — a net gain of 4 holders — while 24 added to existing stakes and 10 trimmed.
The largest buyer was Scoggin Management, opening a new position worth an estimated $1.04M. The largest seller was Vanguard Group, cutting an estimated $3.06M.
- 64 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q4 2022, up from 60 in Q3 2022.
- Funds reported $96.3M of Pear Therapeutics, Inc. Class A Common Stock stock for Q4 2022, down 43% quarter-over-quarter.
- 13 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q4 2022 and 9 closed out, a net change of +4 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q4 2022 was Scoggin Management, an estimated $1.04M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q4 2022 was Vanguard Group, an estimated $3.06M sold.
Based on aggregated 13F filings for Q4 2022.